Samsung Bioepis
Samsung Bioepis announces launch of two new denosumab biosimilars in Europe
December 4, 2025Sales and Marketing Oncology, Osteoporosis, Samsung Bioepis
Samsung Bioepis has announced the European launch of Obodence and Xbryk, two new denosumab biosimilars approved for the treatment of …
Exclusive interview: Samsung Bioepis’ Sang-Jin Pak on the rise of biosimilars
December 2, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Samsung Bioepis, biosimilars, pharma
Following on from our focus on biosimilars in our feature last week, you can read Nikhil Patel’s interview with Sang-Jin …
Biogen scoops up eye and anti-TNF drug rights from Samsung Bioepis in $300m deal
November 7, 2019Sales and Marketing Biogen, Samsung Bioepis, pharma
Biogen has struck a new deal with Samsung Bioepis, it has emerged, picking up the commercialisation rights to a raft …
Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US
July 24, 2019Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma
It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …
FDA approves third Herceptin biosimilar with Samsung Bioepis’ Ontruzant
January 22, 2019Manufacturing and Production, Sales and Marketing FDA, Herceptin, Samsung Bioepis, biosimilar, pharma
Samsung Bioepis’ has announced that the FDA has chosen to approve Ontruzant (trastuzumab-dttb), its biosimilar version of Roche’s Herceptin (trastuzumab), …
MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes
October 15, 2018Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma
MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …
MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar
October 8, 2018Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis
American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …
Samsung BioLogics’ shares down $6bn after accounting furore
May 2, 2018Research and Development, Sales and Marketing Samsung BioLogics, Samsung Bioepis, biotech, drugs, pharma, pharmaceutical, south korea
Samsung BioLogics’ shares have been hit hard, after the South Korean company was handed a notice of suspected breach of …
Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar
April 6, 2018Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma
Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …
Ontruzant launches to become first Herceptin biosimilar available in the UK
March 8, 2018Sales and Marketing Cancer, Herceptin, MSD, Ontruzant, Roche, Samsung Bioepis, pharma
Ontruzant, the biosimilar version of Herceptin (trastuzumab ) originally developed by Korean firm Samsung Bioepis, has launched for patients in …
Samsung Bioepis’ Ontruzant becomes first Herceptin biosimilar approved in Europe
November 20, 2017Sales and Marketing EMA, Herceptin, Roche, Samsung Bioepis
Samsung Bioepis has announced that Ontruzant, the company’s biosimilar version of Roche’s Herceptin, has been awarded marketing authorisation in Europe …
Samsung completes hat-trick of big biosimilar approvals
August 25, 2017Medical Communications, Sales and Marketing Biogen, Samsung Bioepis, biosimilars, biotech, drugs, pharma, pharmaceutical
Samsung Bioepis has announced that it, alongside its partner Biogen, has secured European Commission approval for its biosimilar version of …
Samsung Bioepis collaborates to make inroads into original drugs
August 21, 2017Research and Development, Sales and Marketing Samsung Bioepis, Takeda, biotech, drugs, pharma, pharmaceutical
Thus far, Samsung Bioepis has made its name by being a thorn in the side of the producers of original …
Humira set to face new European biosimilar rival
June 26, 2017Sales and Marketing CHMP, EMA, Samsung Bioepis
A position opinion from the EMA for Samsung Bioepis’ biosimilar of Humira looks set to unleash a second rival to …
J&J launches lawsuit to block release of Remicade biosimilar
May 19, 2017Medical Communications, Sales and Marketing J&J, JJ, Remicade, Samsung Bioepis
Samsung Bioepis gained approval to launch its biosimilar to Johnson & Johnson’s Remicade just last month, on 21 April, but …
Latest content
FibroFind appoints Lee Borthwick as CEO
